Silvio Danese discusses the STARDUST trial looking at the benefits of a treat-to-target strategy for optimising ustekinumab treatment in Crohn’s disease based on endoscopic and clinical outcomes (3:28).
Silvio Danese discusses the STARDUST trial looking at the benefits of a treat-to-target strategy for optimising ustekinumab treatment in Crohn’s disease based on endoscopic and clinical outcomes (3:28).
Don’t fall behind!
Get the latest headlines – in your specialties of choice – delivered straight to your inbox.
medwireNews Deputy Bureau Chief
